<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30122988</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>22</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">1179-1322</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>10</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Cancer management and research</Title>                <ISOAbbreviation>Cancer Manag Res</ISOAbbreviation>            </Journal>            <ArticleTitle>LRH-1 drives hepatocellular carcinoma partially through induction of c-myc and cyclin E1, and suppression of p21.</ArticleTitle>            <Pagination>                <MedlinePgn>2389-2400</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.2147/CMAR.S162887</ELocationID>            <Abstract>                <AbstractText Label="Background" NlmCategory="UNASSIGNED">To explore potential therapeutic target is one of the areas of great interest in both clinical and basic hepatocellular carcinoma (HCC) studies. Nuclear receptor liver receptor homolog-1 (LRH-1, <i>NR5A2</i>) is proved to play a positive role in several cancers including breast cancer, pancreatic cancer and intestinal cancer in recent years. However, the exact role of LRH-1 in the development and progression of HCC is not fully elucidated.</AbstractText>                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">The LRH-1 expression level in HCC clinical samples was examined by immunohis-tochemistry (IHC). Stable LRH-1-suppressed HepG2 clones (HepG2<sup>LRH-1/-</sup>) were generated by transcription activator-like effector nucleases (TALENs) and both in vitro and in vivo experiments were conducted.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">We confirmed that LRH-1 showed an increased expression pattern in HCC clinical samples. Our in vitro and in vivo results indicated that suppression of LRH-1 in HepG2 significantly attenuated its proliferation rate and tumorigenic capacity. Gene expression microarray analysis indicated that LRH-1mostly regulated gene expression involved in cell cycle. In addition, our gain-of-function experiments indicated that ectopic expression of LRH-1 dramatically induced the mRNA and protein levels of c-myc and cyclin E1, while attenuating the expression of p21.</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">Our results suggest that LRH-1 might be a potential therapeutic target for clinical HCC treatment.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y" EqualContrib="Y">                    <LastName>Xiao</LastName>                    <ForeName>Lijia</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Laboratory Medicine, Shenzhen Hospital, Southern Medical University, Shenzhen, China, yiwenzhou21@126.com.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Laboratory, Nanshan Affiliated Hospital of Guangdong Medical University, Shenzhen, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y" EqualContrib="Y">                    <LastName>Wang</LastName>                    <ForeName>Yuliang</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China, franky-chan@cuhk.edu.hk.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liang</LastName>                    <ForeName>Weicheng</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China, franky-chan@cuhk.edu.hk.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Liping</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hepatobiliary and Pancreatic Surgery, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Pan</LastName>                    <ForeName>Nannan</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Laboratory Medicine, Shenzhen Hospital, Southern Medical University, Shenzhen, China, yiwenzhou21@126.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Deng</LastName>                    <ForeName>Huimin</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Laboratory Medicine, Shenzhen Hospital, Southern Medical University, Shenzhen, China, yiwenzhou21@126.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Luqian</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Laboratory Medicine, Shenzhen Hospital, Southern Medical University, Shenzhen, China, yiwenzhou21@126.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zou</LastName>                    <ForeName>Chang</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Clinical Medicine Research Center, Shenzhen Public Service Platform of Precision Medicine and Molecular Diagnosis on Tumor, The Second Clinical Medical College (Shenzhen People's Hospital), Jinan University, Shenzhen, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chan</LastName>                    <ForeName>Franky Leung</ForeName>                    <Initials>FL</Initials>                    <AffiliationInfo>                        <Affiliation>School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China, franky-chan@cuhk.edu.hk.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhou</LastName>                    <ForeName>Yiwen</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Laboratory Medicine, Shenzhen Hospital, Southern Medical University, Shenzhen, China, yiwenzhou21@126.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>01</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>New Zealand</Country>            <MedlineTA>Cancer Manag Res</MedlineTA>            <NlmUniqueID>101512700</NlmUniqueID>            <ISSNLinking>1179-1322</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2015 Mar 1;136(5):E359-86</RefSource>                <PMID Version="1">25220842</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Endocrinol. 2005 Jul;186(1):85-96</RefSource>                <PMID Version="1">16002539</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mech Dev. 1999 Dec;89(1-2):185-8</RefSource>                <PMID Version="1">10559496</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Annu Rev Physiol. 2003;65:261-311</RefSource>                <PMID Version="1">12518001</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nucleic Acids Res. 2016 Jan 29;44(2):582-94</RefSource>                <PMID Version="1">26400164</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nucleic Acids Res. 2011 Jul;39(12):e82</RefSource>                <PMID Version="1">21493687</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cell Biochem. 2008 Jan;308(1-2):93-100</RefSource>                <PMID Version="1">17952562</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genes Dev. 2016 Jun 1;30(11):1255-60</RefSource>                <PMID Version="1">27298334</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Endocrinol Metab. 2003 Dec;88(12):6020-8</RefSource>                <PMID Version="1">14671206</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocrinology. 2009 Aug;150(8):3885-93</RefSource>                <PMID Version="1">19359379</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Exp Mol Med. 2016 Mar 04;48:e213</RefSource>                <PMID Version="1">26940882</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem Biophys Res Commun. 2009 May 15;382(4):756-61</RefSource>                <PMID Version="1">19324023</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocr Relat Cancer. 2010 Oct 29;17(4):965-75</RefSource>                <PMID Version="1">20817789</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>EMBO Rep. 2002 Dec;3(12):1181-7</RefSource>                <PMID Version="1">12446566</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):16927-31</RefSource>                <PMID Version="1">21949357</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cell Biol. 2003 Oct;23(19):6713-24</RefSource>                <PMID Version="1">12972592</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochim Biophys Acta. 2002 Jun 13;1583(1):63-73</RefSource>                <PMID Version="1">12069850</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cell Endocrinol. 2010 Jul 29;323(2):307-13</RefSource>                <PMID Version="1">20214950</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Stem Cells. 2010 Oct;28(10):1794-804</RefSource>                <PMID Version="1">20734354</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2005 Jan 15;65(2):657-63</RefSource>                <PMID Version="1">15695411</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocrinology. 2007 Mar;148(3):1255-65</RefSource>                <PMID Version="1">17170099</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hepatology. 2013 Jun;57(6):2480-90</RefSource>                <PMID Version="1">23315968</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Annu Rev Pathol. 2011;6:345-64</RefSource>                <PMID Version="1">21073338</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Anticancer Res. 2015 Nov;35(11):5737-44</RefSource>                <PMID Version="1">26503994</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cell. 2004 Aug 27;15(4):499-509</RefSource>                <PMID Version="1">15327767</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2015 Aug 20;34(34):4509-18</RefSource>                <PMID Version="1">25435372</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Steroids. 2013 Jul;78(7):700-6</RefSource>                <PMID Version="1">23537609</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biol Chem. 2001 Dec 14;276(50):46822-9</RefSource>                <PMID Version="1">11590139</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biol Chem. 2001 Jul 6;276(27):24767-73</RefSource>                <PMID Version="1">11331284</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Biol Chem. 2001 Apr 20;276(16):13136-44</RefSource>                <PMID Version="1">11145965</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocrinology. 2013 Apr;154(4):1648-60</RefSource>                <PMID Version="1">23471216</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90</RefSource>                <PMID Version="1">21296855</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2058-62</RefSource>                <PMID Version="1">15684064</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocrinology. 2003 Aug;144(8):3598-610</RefSource>                <PMID Version="1">12865342</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2011 Sep 22;365(12):1118-27</RefSource>                <PMID Version="1">21992124</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Invest. 2011 Aug;121(8):3159-75</RefSource>                <PMID Version="1">21747169</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem Biophys Res Commun. 2005 Aug 5;333(3):917-24</RefSource>                <PMID Version="1">15963945</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2005 Dec 8;24(55):8167-75</RefSource>                <PMID Version="1">16091743</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">HCC</Keyword>            <Keyword MajorTopicYN="N">LRH-1</Keyword>            <Keyword MajorTopicYN="N">c-myc</Keyword>            <Keyword MajorTopicYN="N">cyclin E1</Keyword>            <Keyword MajorTopicYN="N">p21</Keyword>        </KeywordList>        <CoiStatement>Disclosure The authors report no conflicts of interest in this work.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>21</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30122988</ArticleId>            <ArticleId IdType="doi">10.2147/CMAR.S162887</ArticleId>            <ArticleId IdType="pii">cmar-10-2389</ArticleId>            <ArticleId IdType="pmc">PMC6078084</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>